ResearchPaperGlobalProteomeandPhospho-proteomeAnalysisofMerlin-deﬁcientMeningiomaandSchwannomaIdentiﬁesPDLIM2asaNovelTherapeuticTargetKayleighBassiria,1,SaraFerlugaa,1,VikramSharmab,NeloferSyedc,ClaireL.Adamsa,EdwinLasonderb,COliverHanemanna,⁎aInstituteofTranslationalandStratiﬁedMedicine,PlymouthUniversityPeninsulaSchoolsofMedicineandDentistry,JohnBullBuilding,PlymouthSciencePark,ResearchWay,Derriford,PlymouthPL68BU,UKbSchoolofBiomedicalandHealthcareSciences,PlymouthUniversity,DrakesCircus,PlymouthPL48AA,UKcJohnFulcherNeuro-oncologyLaboratory,DivisionofBrainSciences,FacultyofMedicine,ImperialCollegeLondon,LondonW68RP,UKabstractarticleinfoArticlehistory:Received10October2016Receivedinrevisedform13January2017Accepted13January2017Availableonline18January2017LossormutationofthetumoursuppressorMerlinpredisposesindividualstodevelopmultiplenervoussystemtumours,includingschwannomasandmeningiomas,sporadicallyoraspartoftheautosomaldominantinheritedconditionNeuroﬁbromatosis2(NF2).Thesetumoursdisplaylargelylowgradefeaturesbuttheirpresencecanleadtosigniﬁcantmorbidity.Surgeryandradiotherapyremaintheonlytreatmentoptionsdespiteyearsofre-search,thereforeaneffectivetherapeuticisrequired.Unbiasedomicsstudieshavebecomepivotalintheidentiﬁcationofdifferentiallyexpressedgenesandproteinsthatmayactasdrugtargetsorbiomarkers.Hereweanalysedtheproteomeandphospho-proteomeofthesege-neticallydeﬁnedtumoursusingprimaryhumantumourcellstoidentifyupregulated/activatedproteinsand/orpathways.Weidentiﬁedover2000proteinsincomparativeexperimentsbetweenMerlin-deﬁcientschwannomaandmeningiomacomparedtohumanSchwannandmeningealcellsrespectively.UsingfunctionalenrichmentanalysiswehighlightedseveraldysregulatedpathwaysandGeneOntologyterms.Weidentiﬁedseveralproteinsandphospho-proteinsthataremorehighlyexpressedintumourscomparedtocontrols.AmongproteinsjointlydysregulatedinbothtumourswefocusedinparticularonPDZandLIMdomainprotein2(PDLIM2)andvalidateditsoverexpressioninseveraltumoursamples,whilenotdetectingitinnormalcells.WeshowedthatshRNAme-diatedknockdownofPDLIM2inbothprimarymeningiomaandschwannomaleadstosigniﬁcantreductionsincellularproliferation.Toourknowledge,thisistheﬁrstcomprehensiveassessmentoftheNF2-relatedmeningiomaandschwannomaproteomeandphospho-proteome.Takentogether,ourdatahighlightseveralcommonlyderegulatedfactors,andindicatethatPDLIM2mayrepresentanovel,commontargetformeningiomaandschwannoma.©2017TheAuthors.PublishedbyElsevierB.V.ThisisanopenaccessarticleundertheCCBY-NC-NDlicense(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:MeningiomaSchwannomaNF2MerlinProteomePhospho-proteome1.IntroductionNeuroﬁbromin2(Merlin,NF2)isatumoursuppressorproteinexpressedduringembryonicdevelopmentandthereafter(Gronholmetal.,2005).Inadults,signiﬁcantlevelsofexpressionarefoundinSchwannandmeningealcells,nerveandlens(Claudioetal.,1997;Sakudaetal.,1996;SchererandGutmann,1996).Mutationsintheencodinggene(NF2)leadtoformationofschwannomasandmeningiomas,andlessoftenofependymomasandretinalastrocytichamartomas(Hanemann,2008;Martinetal.,2010;Rouleauetal.,1993).ThesetumoursoriginatesporadicallyoraspartofthegeneticconditionNeuroﬁbromatosistype2(NF2)(Hanemann,2008).Theyarelargelyunresponsivetoclassicche-motherapeuticagents,leavingsurgeryandradiotherapyastheonlyre-mainingtreatmentoptionswhichcanleavethepatientwithmildtoseveremorbidity(Hanemann,2008).Additionally,NF2patientsoftende-velopmultipletumourssimultaneously(Hanemann,2008),strengthen-ingtheneedforeffectivesystemictherapeuticoptions.LossofMerlinhasalsobeenrelatedtoavarietyofothercancers,includingglioblasto-mas,malignantmesotheliomasandthyroidcarcinomas,highlightingitsroleastumoursuppressor(Garcia-Renduelesetal.,2015;Guerreroetal.,2015;Leeetal.,2016;Morrowetal.,2016;Sheikhetal.,2004).MerlinsharesstructuralsimilaritywiththeEzrin/Radixin/Moesin(ERM)familyofproteinsthatlinkthecytoskeletonwithcomponentsofthecellmembrane(Bretscheretal.,2000;McClatchey,2003;McClatcheyandGiovannini,2005).AlthoughMerlinlackstheC-EBioMedicine16(2017)76–86⁎Correspondingauthorat:JohnBullBuilding,PlymouthSciencePark,ResearchWay,Derriford,PlymouthPL68BU,UK.E-mailaddress:oliver.hanemann@plymouth.ac.uk(C.O.Hanemann).1Theseauthorsequallycontributedtothemanuscript.http://dx.doi.org/10.1016/j.ebiom.2017.01.0202352-3964/©2017TheAuthors.PublishedbyElsevierB.V.ThisisanopenaccessarticleundertheCCBY-NC-NDlicense(http://creativecommons.org/licenses/by-nc-nd/4.0/).ContentslistsavailableatScienceDirectEBioMedicinejournalhomepage:www.ebiomedicine.comterminalactin-bindingdomainpresentintheothermembersoftheERMfamily,itcanlocalizetothecorticalcytoskeletonandinteractdi-rectlywiththeactin-bindingproteinα-catenin(Gladdenetal.,2010).Atsitesofcell-cellcontactMerlinactsastumoursuppressorcontrollingcadherin-mediatedcontact-dependentinhibitionofproliferationandadherensjunctionformation(Flaizetal.,2008;Lallemandetal.,2003).Severalreceptortyrosinekinases(RTKs)havebeenfoundtobeMerlin-dependent(Curtoetal.,2007;Lallemandetal.,2009).Ourgroupandothersshowedoverexpressionandreduceddegradationoftheplatelet-derivedgrowthfactorreceptorβ(PDGFRβ)inschwannomacomparedtonormalSchwanncellswhich,togetherwiththelossofMerlin,leadstoincreasedcellularproliferationandaberrantactivationoftheMAPKandPI3Ksignallingpathways(Ammounetal.,2008;Fraenzeretal.,2003).RTKsarefoundtobelinkedtoMerlinandthusthecytoskeletonviathePDZdomain–containingadapterNHERF-1(Na+/H+exchangerregulatoryfactor)(Maudsleyetal.,2000;Weinmanetal.,2000).MerlinlossfurthercontributestotumorigenesisviatheactivationofanumberofotherpathwaysincludingtheHippo,RasandWnt/β-catenin(Lietal.,2014;Mohleretal.,1999;Zhaoetal.,2010,2011).Merlinactivityisalsointhenucleus,whereitbindstotheE3ubiquitinligaseCRL4(DCAF1)suppressingitsactivity.DepletionofDCAF1inMerlin-deﬁcientschwannomacellswassufﬁcienttoblockproliferation(Cooperetal.,2011).Unbiasedgenomicstudieshavebeenperformedaimingtoidentifynoveldifferentially-expressedgenesinschwannomasandmeningio-mas(Fevre-Montangeetal.,2009;Hanemannetal.,2006;Torres-Martinetal.,2013a,b,2014;Wangetal.,2012)aswellasnoveldrivermutations,exclusiveofNF2(Clarketal.,2013).Massspectrometry(MS)isapowerful,high-throughputtechniquetoidentifythousandsofproteinsaberrantlyexpressedandregulated.RecentlySharmaandcolleaguesperformedcomparativeproteomicanalysisondifferentgradesofmeningiomastoinvestigatealterationsinthemeningiomatissueandinthehumanserumofmeningiomapa-tientscomparedtonormalbraintissue.Theyidentiﬁedseveralderegulatedproteinsincludingtransgelin-2andcaveolinintissue,plusapoliopoproteinsAandEinserum(Sharmaetal.,2014,2015).Hereweanalysedbylabelfreequantitativeproteomicsboththepro-teomeandphospho-proteomeofmeningiomaandschwannomaprimarytumourcells.Byanalysingproteomesandphospho-proteomestogether,weidentifyoverexpressedproteinsintumourcellsandregulatorysignal-lingpathwaysthatmaybe‘switchedoff’withtherapeuticintervention.WealsocomparedproteinabundancesinprimaryMerlin-deﬁcienthumanmeningiomacellsagainsthumanmeningealcells,andprimaryhumanschwannomacellsagainstprimaryhumanSchwanncells.Weidentiﬁednumerousnovelupregulatedanddownregulatedproteinsandphospho-proteins,performedGeneOntology(GO)mappingandfunctionalenrichmentanalysesforGOandpathwayterms.Weidenti-ﬁedproteinscommontobothMerlin-deﬁcienttumourtypes.SeveraloftheupregulatedproteinscontainedeitheraPDZ/LIMdomain,orboth.Theseproteinshavebeenshowntohaveawiderangeofbiologicalfunctionsincludingrolesincellsignalling(TeVelthuisetal.,2007).WefoundPDZandLIMdomainprotein2(PDLIM2/mystique/SLIM)com-monlyupregulatedinbothtumourtypescomparedtothenormalcon-trols.PreviousexperimentsonPDLIM2suggestedaroleincytoskeletalorganizationasitwasco-immunoprecipitatedtogetherwithalpha-actinin-1,alpha-actinin-4,ﬁlaminA,andmyosinheavypolypeptide9inratcornealepithelialcells(Loughranetal.,2005a;Torradoetal.,2004).PDLIM2wasalsoidentiﬁedatthenuclearlevelexertingtumoursuppressivefunctionsbyterminatingNF-κBactivationduringinﬂam-mation(Tanakaetal.,2007)andinbreastcancer(Quetal.,2010).PDLIM2overexpressionwasfoundinmetastaticcancercells(Loughranetal.,2005b)andandrogen-independentprostatecancercelllines(Kangetal.,2016).Usingourprimaryhumanculturesweper-formedPDLIM2silencinginprimaryhumanschwannomasandmenin-giomasandobservedastatisticallysigniﬁcantreductionincellproliferationinbothtumourtypes.Toourknowledge,thisworkistheﬁrstproteomicstudyaimingtodeciphercommonderegulatedelementsintheproteomeandphospho-proteomeofMerlin-deﬁcientschwannomasandmeningiomas.2.MaterialsandMethods2.1.ClinicalSamplesMeningiomaandschwannomaspecimenswerecollectedafterpa-tientsconsentedtothestudyandgivenauniqueMOTidentiﬁcationnumber.ThisstudywasgrantedfullnationalethicsapprovalbytheSouthWestresearchethicscommittee(RECNo:14/SW/0119;IRASpro-jectID:153,351)andlocalresearchanddevelopmentapproval(Plym-outhHospitalsNHSTrust:R&DNo:14/P/056andNorthBristolNHSTrust:R&DNo:3458).NormalhumanSchwanncellswerecollectedafterethicalapprovalundertheRECnumberREC6/Q2103/123.ThebraintumourmaterialwasobtainedfromtheImperialbraintumourbankandthissub-collectioniscoveredbyImperialCollegeTissuebankethics.AllmeningiomasamplesusedinthisstudyweregradeI.2.2.CellCultureHumanmeningealcells(HMC)wereobtainedfromSciencell™andmaintainedinthemanufacturer'srecommendedmediaat5%CO2.HumanprimarySchwann/schwannomacellsweremaintainedasde-scribedpreviously(Rosenbaum2000).Ben-Men-1cellsandprimarymeningiomacellswereroutinelygrowninDMEM,10%FBSand100U/mlPenicillin/Streptomycin,andwerekeptat5%CO2/37°C.2.3.Phospho-proteinPuriﬁcationPhospho-proteinswereisolatedfromcelllysatesusingthecommer-ciallyavailablephospho-proteinpuriﬁcationkitfromQiagen®.Themanufacturersreportedanenrichmentofover80%withlessthan5%phosphorylationintheﬂow-throughfraction.SimilarlyMeimounetal.reportedanenrichmentof88%usingthiskit(Meimounetal.,2007).Theprotocolwascarriedoutaccordingtothemanufacturer'sin-structionsusing2.5mgofstartingmaterial.ProteinconcentrationsweredeterminedbytheBCAproteinassayaccordingtothemanufacturer'sinstructions.2.4.In-gelDigestionCellswerelysedinthebufferprovidedwiththephospho-proteinpuriﬁcationkit.50μgofproteinandcorrespondingisolatedphospho-proteinwereseparatedviaSDS-PAGE.Gelswerestainedwithcolloidalcoomassiebluestain(LifeTechnologies)for3hatroomtemperature(RT).DestainingwasperformedusingMSgradewater(Fisher)over-nightatRT.Individuallaneswerecutintosmall1mm×1mmpiecesbeforein-geldigestionasdescribedpreviously(Lasonderetal.,2002).Theprotocolwasperformedasfollowperslice:equilibrationin200μlof50mMammoniumbicarbonate(ABC)for5minat37°C,destainingin200μlof50%acetonitrile(ACN)/50%H2Ofor5minat37°Cthen200μlof100%ACNfor5minat37°C.Thesestepswereperformedintriplicate.200μlofreductionbuffer(10mMdithiothreitolinABC)wasaddedtothegelslicesandincubatedfor20minat56°C.Sliceswerethenshrunkusing100%ACNfor5minatRTandalkylatedusing200μlofalkylationbuffer(23.35mg2-choloroacetamide,5ml50mMABC)for20minatRTinthedark.Thegelpieceswereincubatedwithdigestionbuffer(12.5ng/μltrypsininABC)overnightat37°C.Digestedpeptideswereextractedbytheadditionof2%Triﬂuoroaceticacid(TFA)tothedigestionbufferincubatedfor20minonashakerat37°C.Peptidesolutionsweretransferredtofreshtubes,and100μlofbufferB(80%ACN,0.5%aceticacid,1%TFA)wasaddedtothegelpiecesandincubatedforafurther20minonashakerat37°C.ThebufferBsolutionwasthencombinedwiththesolutionfromtheﬁrstpeptideextraction,and77K.Bassirietal./EBioMedicine16(2017)76–86sampleswereconcentratedinaDNAcentrifuge(LabconcoCentriVap®)untillessthan40μlofsamplewasleft.SampleswerethendissolvedinbufferA(0.5%aceticacid,1%TFA)priortoMSanalysis.2.5.PeptidePuriﬁcationWithStageTipsStagetipswereassembledbyplacinghighperformanceC18extrac-tiondisksintopipettetipsasdescribed(Rappsilberetal.,2003).50μlofmethanolwasaddedtothepreparedstagetipsandcentrifugeduntilthewholevolumepassedthrough.ThiswasrepeatedwithbufferB(80%acetonitrile,0.5%aceticacid)andthentwicewithbufferA(0.5%aceticacid).Sampleswereaddedtostagetipsandcentrifuged(1min;10,000×gatRT).50μlofbufferAwasthenaddedandcentrifugeduntilallthevolumehadpassedthrough.Peptideswereelutedbyaddi-tionof20μlofbufferBandcentrifugation.Thesampleswereconcen-tratedusingaspeedvacbeforeresuspensioninbufferAtogiveaﬁnalvolumeofapproximately25μl(Rappsilberetal.,2003).2.6.LiquidChromatographyTandemMassSpectrometryMSwascarriedoutusinganUltimate3000UPLCsystem(ThermoFisher,Germany)connectedtoanOrbitrapVelosPromassspectrometer(ThermoFisher,Bremen,Germany).Thepreparedpeptideswereloadedontoa2cmAcclaim™PepMap™100Nano-TrapColumn(ThermoFisher,Germany)andseparatedbya25cmAcclaim™PepMap™100NanoLCcolumn(ThermoFisher,Germany)packedwithC18beadsof3μmandrunninga120mingradientof95%bufferA/5%bufferB(bufferAcontains0.5%aceticacidandbufferBcontains0.5%aceticacidin100%acetonitrile)to65%bufferA/35%bufferBandaﬂowrateof300nl/min.Elutedpeptideswereelectrosprayedintothemassspectrometeratasprayvoltageof2.5kV.TheOrbitrapinstrumentperformsdataacquisi-tioninadatadependentmodetoswitchbetweenMSandMS2.TheOrbitrapcellwitharesolutionof60,000acquiresafull-scanMSspec-trumofintactpeptides(m/z350–1500)withanautomatedgaincontrolaccumulationtargetvalueof1000,0000ions.Inthelineariontrapthetenmostabundantionsareisolatedandfragmentedbyapplyingcolli-sioninduceddissociationusinganaccumulationtargetvalueof10,000,acapillarytemperatureof275°C,andnormalizedcollisionener-gyof30%.Adynamicexclusionofionspreviouslysequencedwithin45swasapplied.Anysinglychargedionsandunassignedchargedstateswereexcludedfromsequencingandaminimumof10,000countswasrequiredforMS2selection.Dynamicexclusionisawidelyusedtoolinmassspectrometrydataacquisitionsoftwareenablingmoreproteinstobeidentiﬁedandincreaseproteomecoverage(Zhangetal.,2009).2.7.ProteinIdentiﬁcationAndromedasearchengineintegratedinMaxQuantversion1.3.05programmewasusedtoidentifytheproteinsintheUniprotdatabase(www.uniprot.org/downloads,November2015)andsupplementedwithsequencesoffrequentlyobservedcontaminants.Amasstoleranceof6ppmfortheparentalpeptideand0.5Daforfragmentationspectraandatrypsinspeciﬁcityallowingupto2mis-cleavedsitesweresetastheAndromedasearchparameters.Fixedmodiﬁcationsofcarboxyamidomethylationofcysteinesandvariablemodiﬁcationsofoxidationofmethionine,deamidationofglutamineandasparaginewereset.Aminimalpeptidelengthof7aminoacidswasset.MaxQuantperformedaninternalmasscalibrationofmeasuredionsandpeptidevalidationbythetargetdecoyapproachasdescribed.Proteinsandpep-tideswithabetterthan1%falsediscoveryrate(FDR)wereacceptediftheyhadbeenidentiﬁedbyatleast2peptidesinoneofthesamples.Sharedpeptidesequences(razorpeptides)weremappedtoproteinsbytheprincipleofmaximumparsimonyinMaxQuant.Proteinswerequantiﬁedbynormalizedsummedpeptideintensitiescomputedaslabelfreequantiﬁcation(LFQ)valuesinMaxQuant1.3.05￼(Coxetal.,2014)LFQdatawasgeneratedintriplicateforallsamples.LFQdatawasgeneratedintriplicateforallsamples.2.8.QuantiﬁcationAnalysisLFQdatageneratedbyMaxquantwereprocessedusingMicrosoftExcelandspeciallydevelopedproteomicssoftware,Perseus(Tyanovaetal.,2016).LFQvaluesforproteinsandphospho-proteinswereLog2transformedandfoldchange(FC)wascalculatedbasedontheequa-tion:AverageLog2LFQtumour-AverageLog2LFQcontrol.Entrieswith0forLFQwerekeptandincludedinthefoldchangecalculations.A2samplet-testwasperformedgeneratingp-valuesforeachidentiﬁedprotein/phospho-protein.Theproteinswithap-valueb0.05werecon-sidereddifferentiallyexpressedandincludedinfurtheranalysis.Signif-icantlychangedphospho-proteinswerecomparedagainstrespectiveproteinchangestoidentifythosethatarerelativelyhighlyupregulatedi.e.displayingalargesigniﬁcantchangeinphosphorylationandasmall-erincreaseoradecreaseinproteinabundance.2.9.FunctionalEnrichmentAnalysisFunctionalenrichmentanalysiswasperformedusingBenjamini-Hochbergmultiplecorrectiontestingintegratedintothedatabaseforannotation,visualizationandintegrateddiscovery(DAVID)software(Huangdaetal.,2009)forGeneOntology(GO)annotationsandforKEGGpathwaysannotations.FunctionalenrichmentanalysiscomparescoverageofGOandpathwaytermsfromsigniﬁcantlydifferentiallyexpressedproteinswithcoverageofthesetermsinadeﬁnedcontrolbackground–inthiscasetheentirehumanproteome.Thisallowspath-ways,biologicalprocesses,molecularfunctionsandproteinsofparticu-larcellularcomponentstobeidentiﬁedthatareproportionallyoverrepresentedintheexperimentaldatasetthantheyareintheback-grounddatasetandcalculatedasfoldenrichment.WeacceptedenrichedGOandpathwaytermswithpadjustedb0.05andFoldEnrichmentN2.Therepresentativestepsinvolvedintargetidentiﬁcationarepre-sentedinFig.S1.2.10.WesternBlottingCellswerelysedinRIPAbufferconsistingof(150mMNaCl,1%Tri-ton-X,0.5%Sodiumdeoxycholate,0.1%SDSand50mMTrispH8.0)be-foreproteinconcentrationwasdeterminedusingacolorimetricBCAproteinassay(Pierce),andimmunoblottingproceededasdescribedpreviously(Kaempchenetal.,2003).SamplesintendedforMSmea-surementwereseparatedusing4–15%gradientpre-castgels(Bio-rad).Theantibodiesusedinthestudyincluded:Merlin(1:1000),pMerlin(1:500),HDAC1(1:1000)andPDLIM2(1:500)fromCellSig-nalingTechnology;PDLIM2(1:500)fromSantaCruzBiotechnologyandGAPDH(1:50.000)fromMillipore.2.11.ImmunoﬂuorescenceMicroscopyForimmunoﬂuorescence,cellsweregrownO/Nonglassslides.ThefollowingdayslideswerewashedtwicewithPBSandﬁxedwith4%Paraformaldehyde(PFA)/PBSfor10min.SlideswerethenwashedtwicewithPBSandcellswerepermeabilizedwith0.2%TritonX-100/PBSfor5minatRT.SlideswerewashedthreetimeswithPBSandblockedfor1hin10%BSA/PBSatRT.Primaryantibodiesweredilutedin5%BSA/PBSandincubatedO/Nat4°C.SlideswerethenwashedthriceinPBSfor5mineachandincubatedwithsecondaryantibodies(1:200,AlexaFluor®,LifeTechnologies),nuclearcounter-stained(DAPI,4μg/ml)andmountedwithProLongDiamondantifademountant(LifeTechnologies).ConfocalmicroscopywasperformedusingaLeicaDMI6000Bmicroscope.78K.Bassirietal./EBioMedicine16(2017)76–862.12.shRNAMediatedGeneSilencingCulturedcellswereseededat80%conﬂuencybeforetransfectionwithlentiviralparticles(10μl/6well,2μllabtek)directedtowardsPDLIM2(Sigma)inthepresenceof5μg/mlpolybrene(SantaCruzbio-technology).Lentiviruswasappliedfor24h,atwhichpointmediumwasremovedandreplacedwithnormalmediumforafurther24h.Pu-romycinwasthenappliedtocellsataconcentrationof5μg/mlforcellselection.Selectiontookplaceover4–5days,atwhichpointcellswerelysedforWesternblotanalysis,orﬁxedandstainedforKi-67expres-sion.FivedifferentshRNAclonesweretested(sequenceclone1:CCGGCTCGGAAGTCTTCAAGATGCTCTCGAGAGCATCTTGAAGACTTCCG-AGTTTTTTG;sequenceclone2:CCGGGCTCTTACATGAGCTAAGTTTCTCGAGAAACTTAGCTCATGTAAGAGCTTTTTTG;sequenceclone3:CCGGGAGGACATACACTGAGAGTCACTCGAGTGACTCTCAGTGTATGTCC-TCTTTTTTG;sequenceclone4:CCGGCCACTGCCTTTGATCAACCTTCTCGAGAAGGTTGATCAAAGGCAGTGGTTTTTTG;sequenceclone5:CCGGGAGCTGTACTGTGAGAAGCATCTCGAGATGCTTCTCACAGTACAGCTCTTTTTTG),clonedintotheplasmidpLKO.1-puro.Clone5wasthemostsuccessfulinknockingdownPDLIM2.2.13.λ-PhosphataseTreatmentandCytoplasmic-nuclearExtractionCellswerelysedinRIPAbuffercontainingproteaseinhibitorsbutnotphosphataseinhibitors.Proteindephosphorylationwasachievedbytreating20μgofproteinlysatewithλ-phosphatase(NewEnglandBiolabs)followingtheinstructionsofthesupplier.Thereactionwasallowedtoproceedfor2hat30°C.Nontreatedsamplewasincubatedinthesamebufferandforthesameamountoftimeat30°Cbutwaterwasaddedinplaceofλ-phosphatase.ToascertainthecellularlocationofPDLIM2,acytoplasmicandnu-clearextractionassay(ThermoScientiﬁc)wasperformed.Primaryad-herentmeningiomacellswereharvestedwithtrypsinandcentrifugedat500gfor5min.ThecellpelletwasthenwashedonceinPBS,trans-ferredtoamicrocentrifugetubeandcentrifugedfor3minat500g.IcecoldCERIreagent(CytoplasmicExtractionReagent,providedwiththekit)wasaddedtothepellet,vortexedvigorouslyfor15sandincubatedonicefor10min.IcecoldCERIIwasthenaddedtothetubeandvortexedfor5sonthehighestsettingbeforeincubationonicefor1min.Thetubewasthencentrifugedfor5minat16,000gandthesu-pernatantimmediatelytransferredtoapre-chilledtube(thecytoplas-micfraction).IcecoldNER(NuclearExtractionReagent,providedwithkit)wasaddedtotheremainingpelletandvortexedfor15s.Afterincu-bationonicefor40minwithrigorousvortexingevery10min,thetubewascentrifugedatmaximumspeedfor10min.Thesupernatant(nucle-arfraction)wastransferredtoacleantubeandbothextractswerestoredat−80°CuntilanalysisbyWesternblot.Theexperimentwasre-peatedintriplicateonthreedifferentmeningiomacellpopulations.TotalHDAC1andGAPDHwereincludedasreferenceproteinsforthenuclearandcytoplasmicfractionsrespectively.3.Results3.1.DifferentialProteinandPhospho-proteinExpressioninSchwannomavs.SchwannCellsThreeprimaryMerlin-deﬁcientschwannoma-derivedcellpopula-tionswereanalysedvs.humanprimarySchwanncells.MerlinstatuswasconﬁrmedbyWesternblotpriortoMSanalysis(Fig.1A).Theglobalproteomeandtheisolatedphospho-proteomeweremeasuredinparal-leltoallowanindirectcomparisonbetweenproteomeandphospho-proteomedata,andalsotoidentifybothphosphorylatedandnon-phos-phorylatedpotentialtargets.Over1559proteins(TableS1a)(peptidesinTableS1c)andover2455phospho-proteins(TableS1b)(peptidesinTableS1d)wereidentiﬁedinprimaryschwannomavs.Schwanncellswitha32%overlap(Fig.S5a).Only16proteinsintheproteomedatasetwerefoundtobesigniﬁcantlyupregulatedwithaLog2FCN1,while93proteinsweredownregulatedwithaLog2FCb−1.AlistofthesigniﬁcantdifferentiallyexpressedproteinsissummarizedinTableS2.Thetopthreeupregulatedincludethefructose-bisphosphatealdolaseC(ALDOC),theproteasomesubunitbetatype-5(PSMB5)andtransgelin(TAGLN),thelatteridentiﬁedalsoinpreviousstudies(Sharmaetal.,2015).Allupregulatedproteinsweregroupedbasedonproteinclassandarerepresentedbyapiechart(Fig.1B).Thelargestproportionofupregulatedproteinswerecytoskeletal(50%).Interest-ingly,11ofthe16upregulatedproteinsinteractwithoneanother,asidentiﬁedbystring.db(Fig.S3).Inthephospho-proteomedataset,122weresigniﬁcantlyupregulatedwithalogfold-changeover1and101phospho-proteinsweresigniﬁcantlydownregulatedwithaLog2FCb−1(TableS3).Amongthemostupregulatedphospho-pro-teinswastheYorkiehomolog(YAP),previouslyshowntobeactiveinschwannoma(Lietal.,2014)aswellasmembersassociatedtotheRaspathway(Ammounetal.,2008;Morrisonetal.,2007).Inordertoidentifyindividualproteinsaberrantlyregulatedthatmaybeinvolvedinproteinsignallingandpathwayactivation,weanalysedthephospho-proteomedatasetwithrespecttowholepath-waysand/orbiologicalprocessesthataresigniﬁcantlyrepresentedusingDAVID(Huangdaetal.,2009).Theupregulatedphospho-proteinsweremappedtoseveralpathways(Fig.1C).Amongthestatisticallyenrichedpathways(Benjamini-HochbergAdjustedpb0.05)represent-edbytheupregulatedproteinswerefocaladhesion(18%,Foldenrich-ment(FE)5),theMAPKpathway(16%,FE3)andregulationoftheactincytoskeleton(12%,FE3),pathwaysthathavepreviouslybeenshowntobeactivatedinschwannoma(Ammounetal.,2014;Schulzeetal.,2002).Amongtheotherderegulatedpathwaysidentiﬁedwereendocytosis(12%,FE3),vascularsmoothmusclecontraction(12%,FE6),neurotrophinsignalling(9%,FE4),glycolysis/gluconeogenesis(7%,FE6).Wealsoperformedfunctionalenrichmentanalysisontheupreg-ulatedphospho-proteindatasettoidentifythemostsigniﬁcantGOterms(Fig.1D).RASproteinsignaltransductionwasidentiﬁedasthemostenrichedbiologicalprocessinlinewiththeroleoftheRaspathwayinschwannoma(Ammounetal.,2008;Morrisonetal.,2007).ThemostenrichedGOtermoverallcorrespondingtoupregulatedphospho-pro-teinsis‘AP-2adaptorcomplex’,linkedtoclathrin-mediatedendocyto-sis.Amongthedownregulatedphospho-proteins,therewassigniﬁcantenrichmentoflysosomalproteins(Fig.S3).TheseareARSA,AGA,CTSD,GUSB,PSAPandSMPD1.CTSD,orCathepsinD,inparticularisassociatedwithcaspase-3inductionofcelldeathanditsdownregula-tionmayberelatedtoschwannomacellsurvival(Pranjoletal.,2015).Inordertoidentifyproteinsthatwerehighlyactivatedwewantedtoidentifythosethatdisplayedarelativelysmallchangeinproteinabun-dancerelativetophospho-proteinexpression.ThesimplestwayofperformingthisanalysiswastoplotbothdatasetsagainsteachotherasLog2FC,allowingforfastvisualidentiﬁcationofthehighlyupregulat-edphospho-proteins(Fig.1E).Foldchangesofsigniﬁcantlychangedphospho-proteins(p-valueb0.05)areplottedontheyaxis,againsttheirrespectiveproteinfoldchanges(irrespectiveofp-value).Themostrelevantdifferenceswerefoundonthetoppartofthegraph;amongthemwefoundseveralcytoskeletal-relatedproteinslikePDLIM2,PDLIM5andPDLIM7,theregulatorofcellpolarityRho-associ-atedproteinkinase1(ROCK1),Filamin-BandVinculin.Numerouswerealsoinvolvedinvesiculartransportlikethealpha-solubleNSFat-tachmentprotein(NAPA),theChargedMultivascularBodyProtein2B(CHMP2B)andtheVacuolarProteinSorting-associated29(VPS29).3.2.DifferentialProteinandPhospho-proteinExpressioninMeningiomavs.MeningealCellsThreeprimaryhumanmeningioma-derivedcellpopulations(MN)andthemeningiomacelllineBenMen-1(Puttmannetal.,2005),wereanalysedagainstHumanMeningealCells(HMC)asnormal79K.Bassirietal./EBioMedicine16(2017)76–86control.AllsampleswereanalysedforMerlinstatusbyWesternblotpriorMS(Fig.2A).InthecomparisonbetweengradeImeningiomaprimarycellsvs.HMC,2582proteinswereidentiﬁed(TableS4a)(peptidesinTableS4c),andafterphospho-proteinenrichment,weidentiﬁed2505phospho-proteins(TableS4b)(peptidesinTableS4d)witha6%overlap(Fig.S5b).186proteinswereupregulated(Log2FCN1)and494weredownregulated(Log2FCb−1)(TableS5).Oftheidentiﬁedphosphopro-teins,478weresigniﬁcantlychangedbetweenthetwocelltypes;35proteinswereupregulated(Log2FCN1)and443weredownregulated(Log2FCb−1)(TableS6).Duetotherelativelylownumberofsigniﬁ-cantlychangedphosphoproteins(35),itwasnotfeasibletodetectsta-tisticallysigniﬁcantenrichedGOandpathwaytermsbyfunctionalenrichmentanalysisinDAVID.WealsotestedthebenignmeningiomacelllineandcomparedBenMen-1cellsvs.HMC,grownandprocessedintriplicateseparatelyandsawa39%overlapbetweenidentiﬁedpro-teinsandphosphoproteins(Fig.S5c).Inthisanalysis3129proteinswereidentiﬁed(TableS7a)(peptidesinTableS7c),176weresigniﬁ-cantlyupregulated(Log2FCN1),and232weresigniﬁcantlydownregu-lated(Log2FCb−1)(TableS8).Amongthemostupregulatedwefoundthetumournecrosisfactorreceptorsuperfamilymember10D(TNFRSF10D),andfewintegrins(ITGB3,ITGA8,ITGA4,ITGA1).Theup-regulatedproteinsweregroupedbasedonproteinclassasbefore;alargenumberofthemwerenucleicacidbinding(29%),cytoskeletal(17%)orreceptorproteins(14%)(Fig.2B).GOenrichmentanalysisofupregulatedproteinsintheproteomedatasetidentiﬁedtermsrelatinglargelytoECMinteraction,collagenandintegrinmediatedsignalling(Fig.S4).Afterphospho-enrichmentweidentiﬁed2770proteins(TableS7b)(peptidesinTableS7d)andatotalof240phospho-proteinswerefoundsigniﬁcantlyupregulated,whilst195weresigniﬁcantlydownreg-ulated(pb0.05,Log2FCN1/b−1,TableS9).Theupregulatedphospho-proteinsweresubmittedforfunctionalenrichmentanalysisusingDAVID.Thetopenrichedpathwayswerespliceosome(25%),ribosome(13%)andcellcycle(13%)(Fig.2C).Proteasomeisrepresentedby11%,meaningaquitesigniﬁcantaberrationintheproteindegradationmachinery,aswellasantigenprocessing(11%),suggestingapossibleimpairedimmuneresponse.Therewasalsosigniﬁcantrepresentationofphospho-proteinsinvolvedinnon-homologousendjoining(NHEJ)(6%)andnucleotideexcisionrepair(10%).Thedatathereforealsoindi-catestheremaybealterationsinDNArepairmechanisms.GOenrich-mentanalysisidentiﬁedsigniﬁcantenrichmentofproteasomeactivatorcomplex(~80fold)andproteasomeactivatoractivity(~60fold),aswellaspositiveregulationofubiquitin-proteinligaseactivity,inlinewithfunctionalenrichmentanalysis(Fig.2D).Signiﬁcantlychangedphospho-proteinswereplottedinagraphagainsttheirrespectivetotalproteinabundances(Fig.2E).Amongthemostinterestingphospho-proteinsidentiﬁedweretransgelin-2(TAGLN2),previouslyfoundoverexpressedinmeningioma(Sharmaetal.,2015);calcyclinbindingprotein(CACYBP),thatcanFig.1.Functionalcomparativeanalysisofschwannomavs.normalSchwanncells.(A)WesternblotshowingMerlinexpressioninnormalhumanSchwanncellsandlossofMerlinexpressioninschwannomas.(B)Piechart,createdusingPANTHER.db,showingtheupregulatedproteinsgroupedbasedonproteinclass.About50%ofthetotalupregulatedproteinsinschwannomaswerecytoskeletal.(C)Piechartshowingtheupregulatedphospho-proteinssubmittedforfunctionalenrichmentanalysisusingDAVID,theﬁgurehighlightsanumberofactivatedpathwaysinschwannomacellsbutnotinnormalSchwanncells.FocaladhesionandMAPKsignallingwerethemostenriched(18%and16%respectively).(D)MostsigniﬁcantlyenrichedGOtermsintheproteinclasses‘molecularfunction’(green),‘cellularcomponent’(blue)and‘biologicalprocess’(red).Ascellularcomponent,theAP-2adaptorcomplexwasfoundhighlyenriched(about80%)aswellasclathrin-mediatedendocytosis(nearly70%and50%)(E)Signiﬁcantlychangedphospho-proteinsinschwannomacellsvs.phospho-proteinsinnormalSchwanncellsplottedagainsttheirrespectiveproteinandphospho-proteinamounts.DatawereplottedasaLog2FCLFQtumour/normal.80K.Bassirietal./EBioMedicine16(2017)76–86actaseitheranoncogeneoratumoursuppressordependingonthetypeofcancer(Topolska-Wosetal.,2016);Deltex3likeE3ubiquitinligase(DTX3L),abletomodulateDNAdamageresponsesrenderingcancercellsresistanttocertainchemotherapydrugs(Thangetal.,2015).Interestingly,therewereseveralphospho-proteinsidentiﬁedasdownregulatedthatarerelatedtoorganizationofthecytoskele-tonlikeJunctionPlakoglobin(JUP),withaLog2FC=−20.663.Pro-teinabundancewasmostlyunalteredindicatingthatdecreasedphosphorylationofJUPintumourcellsisperhapsgrowthpermis-sive.JUP,alsoknownasγ-cateninisstructurallyandfunctionallyre-latedtoβ-catenin.Phosphorylatedβ-cateninwasalsofoundtobedownregulatedinBen-Men-1cells.3.3.SchwannomaandMeningiomaCommonPhospho-proteinsTheamountofcrossoverbetweendifferentiallyexpressedphospho-proteinsinschwannomavs.SchwanncellsandintheBenMen-1vs.HMCdatasetswasasexpectedhigherthanwiththeprimarymeningio-macellsvs.HMCdataset.Intheanalysisbetweensigniﬁcantlychangedphospho-proteinsinBenMen-1cellscomparedwiththoseinprimaryschwannomacells,11werefoundcommonlyupregulatedand4down-regulated(Table1).Thusweusedthismoreinformativedatasetforcomparisonandsubsequentlyveriﬁedexpressioninprimarymeningio-matumours.AmongthecommonlyupregulatedandactivatedproteinsinbothtumoursweconsistentlyﬁndPDLIM2andFilamin-Bagain.Inaddition,weidentiﬁedtheEpidermalgrowthfactorreceptorkinaseSubstrate8-Likeprotein2(EPS8L2),thatwasfoundnothighlyexpressedinthebrainandlinksgrowthfactorstimulationtocytoskele-talreorganizationandtheRas/Racpathway(Offenhauseretal.,2004),andtheSignalTransducerandActivatorofTranscription1alpha/beta(STAT1).Thesubunitbetatype8andtype7oftheproteasomewerealsofoundcommonlyup-anddownregulatedrespectively,againindi-catingproteasomedysregulation.Wedecidedtoperforminitialvalida-tionstudiesonPDLIM2.Thiscandidatewasprioritisedforthefollowingreasons:1.clearabnormalitiesinthecytoskeletonofthesetumourcells(Flaizetal.,2007;Jamesetal.,2008);2.weidentiﬁedseveralupregulat-edproteinscontainingeitheraPDZ/LIMdomainorboth;3.PDLIM2actsbothasanadaptorproteinatthecytoskeletallevel(Torradoetal.,2004)andanE3ubiquitinligaseintothenucleus(Tanakaetal.,2007);previ-ousstudiesidentiﬁedCRL4(DCAF1),anE3ubiquitinligaseimportantinschwannomaformationandrelatedtoMerlin(LiandGiancotti,2010;Lietal.,2010),indicatingthatpossiblytheregulationofE3ubiquitinli-gasesispivotalinthepathogenesisofMerlin-deﬁcienttumours;4)PDLIM2wasalsoidentiﬁedinprimarymeningiomawithalog2FCof2.6comparedwithHMC.3.4.PDLIM2IsOverexpressedinBothSchwannomasandMeningiomasWeanalysedsixschwannomascomparedwithnormalhumanSchwanncellsbyWesternblot.TheproteinwasfoundoverexpressedinfouroutofthesixschwannomascomparedtothenormalSchwanncellexamined(Schwann-0615)(Fig.3A).AsimilaranalysiswasFig.2.Functionalcomparativeanalysisofmeningiomacellsvs.normalHMC.(A)WesternblotshowingMerlinexpressioninnormalHMCandnoMerlinexpressioninmeningiomatumour-derivedcells.(B)Piechartrepresentingtheupregulatedproteins,groupedbasedonproteinclass(PANTHER.db).Thetopthreeupregulatedproteinclassesinmeningiomawererelatedtonucleicacidbinding(29%),thecytoskeleton(17%)andmembranereceptors(14%).(C)Piechartpresentationoftheupregulatedphospho-proteinssubmittedforfunctionalenrichmentanalysisusingDAVID,theﬁgurehighlightsanumberofactivatedpathwaysinmeningiomacellsbutnotinnormalmeningealcells.(D)MostsigniﬁcantlyenrichedGOtermsintheproteinclasses‘molecularfunction’(green),‘cellularcomponent’(blue)and‘biologicalprocess’(red).Amongthemtheproteasomewasfoundthemostenrichedcellularcomponent(about80%)andbiologicalprocess(nearly60%).(E)Signiﬁcantlychangedphospho-proteinsinBenMen-1cellsvs.phospho-proteinsinnormalHMCplottedagainsttheirrespectiveproteinandphospho-proteinamounts.DatawereplottedasaLog2FCLFQtumour/normal.81K.Bassirietal./EBioMedicine16(2017)76–86performedonmeningiomas;wevalidatedPDLIM2overexpressioninBenMen-1cellsandinsixtumour-derivedprimarycellscomparedtonormalHMC(Fig.3B).WealsotestedthelevelofPDLIM2expressionintumourlysatescomparedtonormalmeninges(Fig.3C).InallcasesPDLIM2wasfoundoverexpressedcomparedtonormalcellsortissue.3.5.PDLIM2KnockdownHighlyDecreasesCellularProliferationofMeningi-omaandSchwannomaCellsToinvestigatethefunctionalrelevanceofPDLIM2expressioninschwannomaandmeningiomawesilencedPDLIM2inthreeprimaryschwannomasandthreeprimarymeningiomasusingshRNAlentiviralparticles.PDLIM2expressionwassigniﬁcantlyknockeddowninschwannomascellsasconﬁrmedbyWesternblot(Fig.3D);thisledtoasigniﬁcantreductioninki-67positivecells(pb0.001),reﬂectingasubstantialreductioninproliferationinresponsetotheknockdown(Fig.3F).Thesamewasrepeatedonmeningiomacellsandagainweobservedareductionofproteinexpressionaftersilencing(Fig.3E)leadingtoasigniﬁcantdecreaseincellularproliferationasmeasuredbyaki-67pro-liferationassay(Fig.3G).AltogetherthesedatastronglysuggestthatPDLIM2isinvolvedincellularproliferationinbothschwannomasandmeningiomas.3.6.PDLIM2CanBePhosphoprylatedandLocalisesIntotheNucleusofSchwannomaandMeningiomaCellsQuantitativeproteomicanalysisshowedastatisticallysigniﬁcantin-creaseofPDLIM2inBenMen-1cellscomparedtoHMCafterphospho-proteinenrichment(Fig.4A),suggestingapossiblephosphorylatedstateoftheprotein.Unfortunatelytherearenospeciﬁcphospho-anti-bodiescommerciallyavailableforpPDLIM2,soweperformedaninvitrodephosphorylationassayusinglambdaphosphatase.TheshiftofthePDLIM2immunoreactivebandafterWesternblotanalysisindeedconﬁrmedthephosphorylationonPDLIM2(Fig.4B).PDLIM2waspreviouslyreportedtoactasacytoplasmicprotein(Torradoetal.,2004)andalsoasanuclearprotein(Tanakaetal.,2007),exhibitingdifferentfunctions.TostudythelocalizationofPDLIM2inourcellularmodelsweperformedcytoplasmicandnuclearproteinextractionandexaminedbyWesternblot.PDLIM2wasfoundtolocalizelargelyintothenucleus(Fig.4C)suggestingapossiblefunc-tionasE3ubiquitinligaseaspreviouslyreported(Tanakaetal.,2007).WealsoperformedimmunoﬂuorescentstainingtofurtherdeterminePDLIM2localizationandidentiﬁeditbothinthecytoplasmandthenu-cleusofBenMen-1andprimarymeningiomacells(Fig.4DandE).4.DiscussionTheaimofthisstudywastodeciphertheproteomeandphospho-proteomeofMerlin-deﬁcientschwannomasandmeningiomasrelativetonormalcontrols.Priortothisstudy,therewasonlyonecomparativeanalysisbetweenmeningiomaandschwannomaatthegenomiclevelreportedintheliterature(Torres-Martinetal.,2013b,2014).Weﬁrstanalysedproteomeandphospho-proteomeofschwannomaandmeningiomaseparately,andcomparedthemtotheirnormalcon-trolsinordertoidentifyproteinsandphospho-proteinssigniﬁcantlydifferentiallyexpressedinthetwotumourtypes.Then,wemergedthetwosetsofcandidatesidentifyingthecommondysregulatedpro-teinsbecauseinNF2patientsthesetumoursfrequentlyoccurtogetherandneedtreatment.Ourproteomicanalysiswashighlyinformativeandrevealedmanyproteinsofpotentialinterestineachdataset.However,despitethevastamountofinformationprovidedbythisstudytherearealsosomelimitationsthathavetobeconsidered.Firstly,thisresearchapproachprovidesageneraloverviewaboutdysregulatedproteinsandpath-ways;however,itisimpossibletodetectthewholeproteomeasnon-abundantproteinscannotreachthelevelofdetection.Secondly,phosphoproteomicstudiesrequirealargeamountofstartingmaterialpriorphospho-enrichment;schwannomaandespeciallyhumanprima-rymeningiomacellsgrowatslowrateforalimitednumberofpassages(b7)makingextremelydifﬁculttoobtaintherequiredamountofpro-teins.Likeeveryenrichmenttechnique,therearepossiblefalse-posi-tivesinthedatasetandadditionalvalidationexperimentsareneeded.Theslowproliferationrateofourprimarycellslikelyexplainthere-duceddatasetobtainedfromtheanalysisofprimarymeningiomaswhichwereculturedwithouttheadditionofexternalgrowthfactorstoavoidartiﬁcialmanipulationoftheproteinsignalling.Whileproteomeofwholetumourbiopsiescomparedtonormalme-ningeswouldprovideinformationaboutenvironmentalsignals,herewedecidedtoconductthestudyonprimarytumourcellsandanestablishedmeningiomacellline,onwhichitwaspossibletoperformsubsequentfunctionalvalidation.Usingpuretumourcellpopulationsinsteadoftissuealsomakesthecomparisonbetweentumoursmoremeaningfulasdifferenttissuewouldvaryinthetumourmicroenvironment.Inschwannomas,byfunctionalenrichmentanalysis,weidentiﬁedseveralfactorsrelatedtothecytoskeletonanditsregulation,inlinewiththepivotalroleofMerlinascytoskeletalregulator(Gladdenetal.,2010;Johnsonetal.,2002;Lallemandetal.,2003;McClatcheyandGiovannini,2005).MAPKsignallingwasalsofoundenriched,inagree-mentwithpreviousstudies(Ammounetal.,2008;Fraenzeretal.,2003).Endocytosis,possiblyclathrin-mediated,waslistedamongtheupregulatedpathwaysandcellularcomponentsinschwannoma,aswellastheAP-2adaptorcomplexrequiredtointernalizecargoinclathrin-mediatedendocytosis(McMahonandBoucrot,2011).ThisisinkeepingwithpreviousdatainﬂiesthatshowedMerlinisimportantforcontrollingmembraneproteinturnoverinpartbyregulatingendo-cytosis(Maitraetal.,2006).Whentheproteomeandphospho-prote-omewerecomparedinordertoidentifyhighlyactivatedproteins,weidentiﬁedseveralcytoskeletalproteinslikePDLIM2,FilaminB,VinculinandthekinaseROCK1,akeyregulatoroftheactincytoskeletonandcellpolarity,andpreviouslyassociatedwiththeERMfamily(Hebertetal.,2008).Again,werecognizedproteinsrelatedtoendocytosisandvesicletransportlikePACSIN3,NAPA,CHMP2BandVPS29.Asopposedtoschwannomas,otherdrivermutationshavebeeniden-tiﬁedinmeningioma,butthosearemutuallyexclusiveofMerlin(Clarketal.,2013).Inordertokeepthegeneticbackgroundconsistentwithschwannoma,weanalysedonlyMerlin-deﬁcientWHOgradeITable1Phospho-proteinscommonlyandsigniﬁcantlyup-ordownregulatedinBenMen-1andprimaryschwannomacells(pb0.05).GenesymbolProteinnameLog2FCmeningiomaLog2FCschwannomaCORO1CCoronin-1C2.601.45CTPSCTPsynthase11.233.70CUTAProteinCutA1.441.50EPS8L2Epidermalgrowthfactorreceptorkinasesubstrate8-likeprotein23.3624.27FLNBFilamin-B1.2224.49HSPA1AHeatshock70kDaprotein1A/1B1.213.23PDE1CCalcium/calmodulin-dependent3,5-cyclicnucleotidephosphodiesterase1C3.161.36PDLIM2PDZandLIMdomainprotein23.9424.53PSMB8Proteasomesubunitbetatype-81.401.29STAT1Signaltransducerandactivatoroftranscription1-alpha/beta4.5726.24TCEB2TranscriptionelongationfactorBpolypeptide21.011.02MAP1AMicrotubule-associatedprotein1A−19.89−1.00PACSIN2ProteinkinaseCandcaseinkinasesubstrateinneuronsprotein2−2.11−1.19PSMB7Proteasomesubunitbetatype-7−1.17−1.32UFL1E3UFM1-proteinligase1−1.14−1.4382K.Bassirietal./EBioMedicine16(2017)76–86meningiomas.Comparativefunctionalenrichmentanalysisintheme-ningiomadatasetsidentiﬁedpathwaysthatmightbeofparticularimpor-tance;amongthemwefoundproteasomeactivationtobearecurringthemethroughout,highlightingitasanimportanttargetinmeningioma.A2014studylookingattheproteasomeinhibitorbortezomibshowedthatitwaseffectiveinsensitizingmeningiomacellstoTRAIL-inducedap-optosis(Koschnyetal.,2014).Further,theproteasomeinhibitorMG132wasalsofoundtoincreaselevelsofN-cadherininschwannomacells,whichinturndecreasedproliferation(Zhouetal.,2011).Ourdataandpreviousreportsthussuggestproteasomeinhibitionasapotentialther-apy,eitheraloneorincombinationwithdrugstargetingotherrelevantpathways.ThephosphorylatedproteinwiththelargestfoldchangeinprimarymeningiomacellswasTGM2,ortransglutaminase2.Theex-pressionofthisproteinhasbeenpreviouslystudiedinmeningiomaandwasfoundtobehighlyupregulatedandsuggestedasatherapeutictarget.TheauthorsalsoshowedthatlossoftheNF2genewasassociatedwithhighexpressionofTGM2(Huangetal.,2014).WealsofoundTAGLN2asupregulatedinmeningiomacells,inkeepingwithpreviousproteomicstudiesonmeningioma(Sharmaetal.,2015).Itissimilarinitsfunctiontotransgelin(TAGLN),whichweidentiﬁedashighlyexpressedinschwannoma.Thetransgelinsareafamilyofproteinsabletoinﬂuenceadiverserangeofcellularprocesses,includingproliferation,migrationandapoptosis(Dvorakovaetal.,2014).ThestudybySharmaetal.usedasimilarproteomicapproachtoidentifypotentialtherapeutictargetsusingmeningiomatissue(comparedtonormalbrain)asopposedtocells.Therewere12proteinssigniﬁcantlyupregulatedandcommontobothdatasetsincludingtheLIMdomaincontainingproteinFHL1,drebrin,ﬁbronectinandtranslationallycontrolledtumourprotein(TCTP),alllinkedwithstructuralregulation.WealsoidentiﬁedpossiblealterationsinDNArepairmechanisms,consistentlywithpreviousresultsshowingchromosomeinstabilityanddefectsinthemitoticapparatusinmeningioma(vanTilborgetal.,2005),inparticularintheNF2-mutated(Goutagnyetal.,2010).StudiesbyYangetal.(2012)showedthatthetumoursuppressorCHEK2onchromosome22qisoftendeletedtogetherwithMerlin,thusimpairingDNArepairmechanismsandincreasingchromosomalinstabilityinme-ningiomas(Yangetal.,2012).BenMen-1cells,whichhaveaknownNF2mutation,havebeenusedasaWHOgradeImeningiomacelllinemodelandcomparedtoHMC,bearinginmindpossiblemodiﬁcationsduetoimmortalization(Puttmannetal.,2005),howeverhelpingthestudybybeinganhomo-geneouspopulationofcells.ThecomparisonbetweenBenMen-1andFig.3.PDLIM2overexpressedinschwannomasandmeningiomasislinkedtoincreasedproliferationoftumourcells.(A)WesternblotanalysisofPDLIM2expressioninprimaryschwannomacellscomparedtoprimaryhumanSchwanncell.(B–C)WesternblotanalysisofPDLIM2expressioninBenMen-1andprimarymeningiomacellscomparedtoHMC(B),andmeningiomatumourspecimenscomparedtonormalhumanmeninges(C).(D)PDLIM2shRNA-mediatedknockdowninthreeprimaryschwannomas,conﬁrmedbytheabsenceofimmunoreactivebandinWesternblotanalysiscomparedtothesh-scramblecontrol.Thesamplesanalysedwere;(1)NF1:NF1115(Fig.3A),Merlin-positiveandpMerlin-positive,NF0116;(2)NF2:NF0116,Merlin-positiveandpMerlinfaintband(datanotshown);(3)NF3:NF0216,Merlin-negativeandpMerlin-negative(datanotshown).(E)PDLIM2shRNA-mediatedknockdowninthreeprimarymeningiomacells,conﬁrmedbythereductionofintensityoftheimmunoreactivebanddetectedbyWesternblotanalysiscomparedtothesh-Scramblecontrol.Thesamplesanalysedwere;(1)MN1:MN026,Merlin-negativeandpMerlin-negative(datanotshown),(2)MN2:MN028,and(3)MN3:MN031,bothMerlin-negativeandpMerlin-negative(Fig.3B).(F)Ki-67immunoﬂuorescentstaining(green)ofthethreeschwannomacellpopulationsafterPDLIM2shRNAknockdowncomparedtosh-Scramblecontrol.Ontheleftsidethehistogramshowingthehighlystatisticallysigniﬁcant(***,pb0.001)reducedproliferationinPDLIM2knockdowncells.(G)Ki-67immunoﬂuorescentstaining(green)ofthethreeprimarymeningiomacellsafterPDLIM2shRNAknockdowncomparedtosh-Scramblecontrol.Ontheleftsidethehistogramshowingthestatisticallysigniﬁcant(*,pb0.05)reducedproliferationinPDLIM2knockdowncells.NucleiarestainedwithDAPI(Blue).Micrographsaretakenat20×magniﬁcation.SC-Scramble;KD-knockdown.83K.Bassirietal./EBioMedicine16(2017)76–86schwannomadatasetscomparedwithcontrolsrevealedseveralcom-monupregulatedproteins.Amongthemweidentiﬁedtheepidermalgrowthfactorreceptorkinasesubstrate8-likeprotein2(EPS8L2),partoftheEPSfamilyofproteinsrelatedtoactincytoskeletonreorganizationundergrowthfactorsstimulation(Offenhauseretal.,2004);thecyto-skeletalproteinFilamin-B(FLNB);andthesignaltransducerandactiva-toroftranscription1-alpha/beta(STAT1),partoftheJAK/STAT1activatedinresponsetointerferonandpreviouslyfoundexpressedinmeningiomas(Magrassietal.,1999),currentlyundervalidation.HerewedecidedtofurtheranalysePDLIM2forseveralreasons;weidentiﬁedseveralPDZ/LIMdomainsproteinsthroughoutthestudy,in-dicatingapossiblyimportantroleofthisfamilyofproteinsinMerlin-deﬁcienttumours.PDLIM2wasﬁrstdescribedin2004asanadaptorproteinlinkingotherproteinstothecytoskeleton(Torradoetal.,2004),soitsdysregulationinMerlin-deﬁcienttumoursappearedhighlyplausible.Since,ithasbeenfoundtohaveanumberofdifferentrolesandhasbeenparticularlywellstudiedinbreastcancerwhereithasbeenidentiﬁedasadriveroftumourprogressionandinvasion(Deevietal.,2014;Loughranetal.,2005a).In2007,fortheﬁrsttimePDLIM2wasshowntopossessnuclearubiquitinE3ligaseactivitynegativelyregulatingNF-kappaBbytargetingthep65subunitduringinﬂamma-tion(Tanakaetal.,2007).PreviousstudiesalreadyidentiﬁedanotherE3ubiquitinligase,CRL4(DCAF1),involvedintheformationofMerlin-deﬁcienttumours(Cooperetal.,2011;Lietal.,2010).Finally,thedys-regulatedubiquitinligaseactivity,togetherwiththedysregulatedproteasomalactivityfoundinmeningiomasinourstudy,cansuggestnoveltherapeuticstrategies.WeﬁrstconﬁrmedPDLIM2overexpressioninprimarymeningiomaandschwannomasamplesandshowedthatitisnotexpressedinHMCornormalmeningealtissueandminimallyexpressedintheSchwanncellexamined.PDLIM2wassigniﬁcantlyknockeddowninthreeprima-rymeningiomaandthreeprimaryschwannomacellpopulations.Thisledtosigniﬁcantreductionsincellproliferationinbothcelltypes.TheseresultsareinlinewithapreviousstudywhichshowedhowPDLIM2suppressionleadstodecreasedproliferationinandrogen-inde-pendentprostatecancercelllines(Kangetal.,2016).Ontheotherhand,otherstudieshaveidentiﬁedPDLIM2asanimportanttumoursuppres-sor(Sunetal.,2015;Zhaoetal.,2016).Interestinglyenough,PDLIM5,thatwefoundhighlyoverexpressedintheschwannomaphospho-pro-teome,wasfoundoverexpressedingastriccancercellsanditssiRNA-Fig.4.PDLIM2actsasphosphoproteinandlocalisesintothenucleus.(A)HistogramshowingPDLIM2MSquantiﬁcationasLog2LFQvalueinBenMen-1(BM)cellsvs.HMCafterphosphoenrichment.PhosphorylatedPDLIM2wasstatisticallysigniﬁcantlyenrichedinBenMen-1cells(**,pb0.012)comparedtoHMC.(B)WesternblotanalysisconﬁrmingthephosphorylatedstatusofPDLIM2inBenMen-1cells.Lambdaphosphatasetreatment(λ-Ph)inducedindeedashiftinPDLIM2immunoreactivebandcomparedtonon-treated(NT)control.(C)RepresentativeWesternblotshowingPDLIM2localizationafternuclearandcytoplasmicproteinfractionation.TotalHDAC1andGAPDHareshownasreferenceproteinforthenuclearandcytoplasmicfractionrespectively.(D)Confocalmicroscopy(Z-stacks)ofPDLIM2(red)inBenMen-1cellsandinprimarymeningiomacells(MN028,MN033,MN036)(E).NucleiwerestainedwithDAPI(blue).84K.Bassirietal./EBioMedicine16(2017)76–86mediatedsilencingsigniﬁcantlyreducedcellularproliferation(Lietal.,2015),highlightingapossiblecommonroleforthisfamilyasregulatorsofcellproliferation.OurresultsshowedthatPDLIM2canbephosphorylated.RecentlyoneproteomicstudyidentiﬁedspeciﬁcphosphoserinesitesonPDLIM2(Bianetal.,2014);however,nophosphospeciﬁcantibodiesareavailableandtheresultneedsfurthervalidation.Uponsubcellularfractionation,PDLIM2wasfoundtolocalizeintothenucleus,possiblyexploitingE3ubiquitinligaseactivity(Tanakaetal.,2007).ICCanalysisshoweditlocalisedtoboththenucleusandthecytoplasm.ItmaybethatPDLIM2associateswiththecytoskeletonandisthusrenderedinsolubleduringsubcellularfractionation,asisthecasewithsomecytoskeletalproteinse.g.intermediateﬁlaments,explainingwhyonlynuclearPDLIM2wasdetectableviaWesternblot.OuroverallresultsindicatethatPDLIM2hasbothnuclearandcytoplas-micfunctionsinmeningiomacells.Additionalstudieswillbeperformedtoverifywhethertheproteinactsonp65eveninMerlin-negativeme-ningiomasandschwannomas,andtheroleofthephosphorylationonPDLIM2activity.Inconclusion,weperformedacomprehensiveanalysisofproteomeandphosphoproteomeexpressioninMerlin-deﬁcientschwannomasandmeningiomas,foundseveraldysregulatedproteins/pathwaysineachdatasetandunderlyingknownandnovelcandidatesinvolvedinthepathogenesisofbothtumours.Additionally,wevalidatedtheover-expressionofPDLIM2whichwasfoundinvolvedintheproliferationofbothmeningiomaandschwannomacells,conﬁrmingthatPDLIM2war-rantsfurtherinvestigationasapotentialcommontargetinMerlin-deﬁ-cientmeningiomasandschwannomas.Supplementarydatatothisarticlecanbefoundonlineathttp://dx.doi.org/10.1016/j.ebiom.2017.01.020.FundingSourcesThisstudywassupportedbygrantsfromDHT(Dr.HadwenTrust);BrainTumourResearchandtheBiochemicalSociety(EricReidFundforMethodology).AcknowledgementWethankDr.DavidHiltonforprovidingtumourspecimens,thesur-geonsfromPlymouthandBristolhospitalsandDr.EmanuelaErcolanoforhelpingwithprimarycellcultures.ReferencesAmmoun,S.,Flaiz,C.,Ristic,N.,Schuldt,J.,Hanemann,C.O.,2008.Dissectingandtargetingthegrowthfactor-dependentandgrowthfactor-independentextracellularsignal-regulatedkinasepathwayinhumanschwannoma.CancerRes.68,5236–5245.Ammoun,S.,Provenzano,L.,Zhou,L.,Barczyk,M.,Evans,K.,Hilton,D.A.,Haﬁzi,S.,Hanemann,C.O.,2014.Axl/Gas6/NFkappaBsignallinginschwannomapathologicalproliferation,adhesionandsurvival.Oncogene33,336–346.Bian,Y.,Song,C.,Cheng,K.,Dong,M.,Wang,F.,Huang,J.,Sun,D.,Wang,L.,Ye,M.,Zou,H.,2014.AnenzymeassistedRP-RPLCapproachforin-depthanalysisofhumanliverphosphoproteome.J.Proteome96,253–262.Bretscher,A.,Chambers,D.,Nguyen,R.,Reczek,D.,2000.ERM-MerlinandEBP50proteinfamiliesinplasmamembraneorganizationandfunction.Annu.Rev.CellDev.Biol.16,113–143.Clark,V.E.,Erson-Omay,E.Z.,Serin,A.,Yin,J.,Cotney,J.,Ozduman,K.,Avşar,T.,Li,J.,Murray,P.B.,Henegariu,O.,Yilmaz,S.,Günel,J.M.,Carrión-Grant,G.,Yilmaz,B.,Grady,C.,Tanrikulu,B.,Bakircioğlu,M.,Kaymakçalan,H.,Caglayan,A.O.,Sencar,L.,Ceyhun,E.,Atik,A.F.,Bayri,Y.,Bai,H.,Kolb,L.E.,Hebert,R.M.,Omay,S.B.,Mishra-Gorur,K.,Choi,M.,Overton,J.D.,Holland,E.C.,Mane,S.,State,M.W.,Bilgüvar,K.,Baehring,J.M.,Gutin,P.H.,Piepmeier,J.M.,Vortmeyer,A.,Brennan,C.W.,Pamir,M.N.,Kiliç,T.,Lifton,R.P.,Noonan,J.P.,Yasuno,K.,Günel,M.,2013.Genomicanalysisofnon-NF2meningiomasrevealsmutationsinTRAF7,KLF4,AKT1,andSMO.Science339,1077–1080.Claudio,J.O.,Veneziale,R.W.,Menko,A.S.,Rouleau,G.A.,1997.ExpressionofschwannomininlensandSchwanncells.Neuroreport8,2025–2030.Cooper,J.,Li,W.,You,L.,Schiavon,G.,Pepe-Caprio,A.,Zhou,L.,Ishii,R.,Giovannini,M.,Hanemann,C.O.,Long,S.B.,Erdjument-Bromage,H.,Zhou,P.,Tempst,P.,Giancotti,F.G.,2011.Merlin/NF2functionsupstreamofthenuclearE3ubiquitinligaseCRL4DCAF1tosuppressoncogenicgeneexpression.Sci.Signal.4(pt6).Cox,J.,Hein,M.Y.,Luber,C.A.,Paron,I.,Nagaraj,N.,Mann,M.,2014.Accurateproteome-widelabel-freequantiﬁcationbydelayednormalizationandmaximalpeptideratioextraction,termedMaxLFQ.Mol.Cell.Proteomics13,2513–2526.Curto,M.,Cole,B.K.,Lallemand,D.,Liu,C.H.,McClatchey,A.I.,2007.Contact-dependentin-hibitionofEGFRsignalingbyNf2/Merlin.J.CellBiol.177,893–903.Deevi,R.K.,Cox,O.T.,O'Connor,R.,2014.EssentialfunctionforPDLIM2incellpolarizationinthree-dimensionalculturesbyfeedbackregulationofthebeta1-integrin-RhoAsig-nalingaxis.Neoplasia16,422–431.Dvorakova,M.,Nenutil,R.,Bouchal,P.,2014.Transgelins,cytoskeletalproteinsimplicatedindifferentaspectsofcancerdevelopment.ExpertRev.Proteomics11,149–165.Fevre-Montange,M.,Champier,J.,Durand,A.,Wierinckx,A.,Honnorat,J.,Guyotat,J.,Jouvet,A.,2009.Microarraygeneexpressionproﬁlinginmeningiomas:differentialexpressionaccordingtogradeorhistopathologicalsubtype.Int.J.Oncol.35,1395–1407.Flaiz,C.,Kaempchen,K.,Matthies,C.,Hanemann,C.O.,2007.Actin-richprotrusionsandnonlocalizedGTPaseactivationinMerlin-deﬁcientschwannomas.J.Neuropathol.Exp.Neurol.66,608–616.Flaiz,C.,Utermark,T.,Parkinson,D.B.,Poetsch,A.,Hanemann,C.O.,2008.Impairedinter-cellularadhesionandimmatureadherensjunctionsinmerlin-deﬁcienthumanpri-maryschwannomacells.Glia56,506–515.Fraenzer,J.T.,Pan,H.,MinimoJr.,L.,Smith,G.M.,Knauer,D.,Hung,G.,2003.Overexpres-sionoftheNF2geneinhibitsschwannomacellproliferationthroughpromotingPDGFRdegradation.Int.J.Oncol.23,1493–1500.Garcia-Rendueles,M.E.,Ricarte-Filho,J.C.,Untch,B.R.,Landa,I.,Knauf,J.A.,Voza,F.,Smith,V.E.,Ganly,I.,Taylor,B.S.,Persaud,Y.,Oler,G.,Fang,Y.,Jhanwar,S.C.,Viale,A.,Heguy,A.,Huberman,K.H.,Giancotti,F.,Ghossein,R.,Fagin,J.A.,2015.NF2losspromotesoncogenicRAS-inducedthyroidcancersviaYAP-dependenttransactivationofRASproteinsandsensitizesthemtoMEKinhibition.CancerDiscov.5,1178–1193.Gladden,A.B.,Hebert,A.M.,Schneeberger,E.E.,McClatchey,A.I.,2010.TheNF2tumorsup-pressor,Merlin,regulatesepidermaldevelopmentthroughtheestablishmentofajunctionalpolaritycomplex.Dev.Cell19,727–739.Goutagny,S.,Yang,H.W.,Zucman-Rossi,J.,Chan,J.,Dreyfuss,J.M.,Park,P.J.,Black,P.M.,Giovannini,M.,Carroll,R.S.,Kalamarides,M.,2010.Genomicproﬁlingrevealsalterna-tivegeneticpathwaysofmeningiomamalignantprogressiondependentontheun-derlyingNF2status.Clin.CancerRes.16,4155–4164.Gronholm,M.,Teesalu,T.,Tyynela,J.,Piltti,K.,Bohling,T.,Wartiovaara,K.,Vaheri,A.,Carpen,O.,2005.CharacterizationoftheNF2proteinmerlinandtheERMproteinezrininhuman,rat,andmousecentralnervoussystem.Mol.Cell.Neurosci.28,683–693.Guerrero,P.A.,Yin,W.,Camacho,L.,Marchetti,D.,2015.OncogenicroleofMerlin/NF2inglioblastoma.Oncogene34,2621–2630.Hanemann,C.O.,2008.Magicbuttreatable?Tumoursduetolossofmerlin.Brain131,606–615.Hanemann,C.O.,Bartelt-Kirbach,B.,Diebold,R.,Kampchen,K.,Langmesser,S.,Utermark,T.,2006.DifferentialgeneexpressionbetweenhumanschwannomaandcontrolSchwanncells.Neuropathol.Appl.Neurobiol.32,605–614.Hebert,M.,Potin,S.,Sebbagh,M.,Bertoglio,J.,Breard,J.,Hamelin,J.,2008.Rho-ROCK-de-pendentezrin-radixin-moesinphosphorylationregulatesFas-mediatedapoptosisinJurkatcells.J.Immunol.181,5963–5973.Huangda,W.,Sherman,B.T.,Lempicki,R.A.,2009.SystematicandintegrativeanalysisoflargegenelistsusingDAVIDbioinformaticsresources.Nat.Protoc.4,44–57.Huang,Y.C.,Wei,K.C.,Chang,C.N.,Chen,P.Y.,Hsu,P.W.,Chen,C.P.,Lu,C.S.,Wang,H.L.,Gutmann,D.H.,Yeh,T.H.,2014.Transglutaminase2expressionisincreasedasafunc-tionofmalignancygradeandnegativelyregulatescellgrowthinmeningioma.PLoSOne9,e108228.James,M.F.,Lelke,J.M.,Maccollin,M.,Plotkin,S.R.,Stemmer-Rachamimov,A.O.,Ramesh,V.,Gusella,J.F.,2008.ModelingNF2withhumanarachnoidalandmeningiomacellculturesystems:NF2silencingreﬂectsthebenigncharacteroftumorgrowth.Neurobiol.Dis.29,278–292.Johnson,K.C.,Kissil,J.L.,Fry,J.L.,Jacks,T.,2002.CellulartransformationbyaFERMdomainmutantoftheNf2tumorsuppressorgene.Oncogene21,5990–5997.Kaempchen,K.,Mielke,K.,Utermark,T.,Langmesser,S.,Hanemann,C.O.,2003.Upregula-tionoftheRac1/JNKsignalingpathwayinprimaryhumanschwannomacells.Hum.Mol.Genet.12,1211–1221.Kang,M.,Lee,K.H.,Lee,H.S.,Park,Y.H.,Jeong,C.W.,Ku,J.H.,Kim,H.H.,Kwak,C.,2016.PDLIM2suppressionefﬁcientlyreducestumorgrowthandinvasivenessofhumancastration-resistantprostatecancer-likecells.Prostate76,273–285.Koschny,R.,Boehm,C.,Sprick,M.R.,Haas,T.L.,Holland,H.,Xu,L.X.,Krupp,W.,Mueller,W.C.,Bauer,M.,Koschny,T.,Keller,M.,Sinn,P.,Meixensberger,J.,Walczak,H.,Ganten,T.M.,2014.BortezomibsensitizesprimarymeningiomacellstoTRAIL-in-ducedapoptosisbyenhancingformationofthedeath-inducingsignalingcomplex.J.Neuropathol.Exp.Neurol.73,1034–1046.Lallemand,D.,Curto,M.,Saotome,I.,Giovannini,M.,McClatchey,A.I.,2003.NF2deﬁciencypromotestumorigenesisandmetastasisbydestabilizingadherensjunctions.GenesDev.17,1090–1100.Lallemand,D.,Manent,J.,Couvelard,A.,Watilliaux,A.,Siena,M.,Chareyre,F.,Lampin,A.,Niwa-Kawakita,M.,Kalamarides,M.,Giovannini,M.,2009.Merlinregulatestrans-membranereceptoraccumulationandsignalingattheplasmamembraneinprimarymouseSchwanncellsandinhumanschwannomas.Oncogene28,854–865.Lasonder,E.,Ishihama,Y.,Andersen,J.S.,Vermunt,A.M.,Pain,A.,Sauerwein,R.W.,Eling,W.M.,Hall,N.,Waters,A.P.,Stunnenberg,H.G.,Mann,M.,2002.AnalysisofthePlas-modiumfalciparumproteomebyhigh-accuracymassspectrometry.Nature419,537–542.Lee,H.,Hwang,S.J.,Kim,H.R.,Shin,C.H.,Choi,K.H.,Joung,J.G.,Kim,H.H.,2016.Neuroﬁ-bromatosis2(NF2)controlstheinvasivenessofglioblastomathroughYAP-85K.Bassirietal./EBioMedicine16(2017)76–86dependentexpressionofCYR61/CCN1andmiR-296-3p.Biochim.Biophys.Acta1859,599–611.Li,W.,Giancotti,F.G.,2010.Merlin'stumorsuppressionlinkedtoinhibitionoftheE3ubiquitinligaseCRL4(DCAF1).CellCycle9,4433–4436.Li,W.,You,L.,Cooper,J.,Schiavon,G.,Pepe-Caprio,A.,Zhou,L.,Ishii,R.,Giovannini,M.,Hanemann,C.O.,Long,S.B.,Erdjument-Bromage,H.,Zhou,P.,Tempst,P.,Giancotti,F.G.,2010.Merlin/NF2suppressestumorigenesisbyinhibitingtheE3ubiquitinligaseCRL4(DCAF1)inthenucleus.Cell140,477–490.Li,W.,Cooper,J.,Zhou,L.,Yang,C.,Erdjument-Bromage,H.,Zagzag,D.,Snuderl,M.,Ladanyi,M.,Hanemann,C.O.,Zhou,P.,Karajannis,M.A.,Giancotti,F.G.,2014.Mer-lin/NF2loss-driventumorigenesislinkedtoCRL4(DCAF1)-mediatedinhibitionofthehippopathwaykinasesLats1and2inthenucleus.CancerCell26,48–60.Li,Y.,Gao,Y.,Xu,Y.,Sun,X.,Song,X.,Ma,H.,Yang,M.,2015.si-RNA-mediatedknockdownofPDLIM5suppressesgastriccancercellproliferationinvitro.Chem.Biol.DrugDes.85,447–453.Loughran,G.,Healy,N.C.,Kiely,P.A.,Huigsloot,M.,Kedersha,N.L.,O'Connor,R.,2005a.Mystiqueisanewinsulin-likegrowthfactor-I-regulatedPDZ-LIMdomainproteinthatpromotescellattachmentandmigrationandsuppressesAnchorage-indepen-dentgrowth.Mol.Biol.Cell16,1811–1822.Loughran,G.,Huigsloot,M.,Kiely,P.A.,Smith,L.M.,Floyd,S.,Ayllon,V.,O'Connor,R.,2005b.GeneexpressionproﬁlesincellstransformedbyoverexpressionoftheIGF-Ireceptor.Oncogene24,6185–6193.Magrassi,L.,De-Fraja,C.,Conti,L.,Butti,G.,Infuso,L.,Govoni,S.,Cattaneo,E.,1999.Expres-sionoftheJAKandSTATsuperfamiliesinhumanmeningiomas.J.Neurosurg.91,440–446.Maitra,S.,Kulikauskas,R.M.,Gavilan,H.,Fehon,R.G.,2006.ThetumorsuppressorsMerlinandexpandedfunctioncooperativelytomodulatereceptorendocytosisandsignal-ing.Curr.Biol.16,702–709.Martin,K.,Rossi,V.,Ferrucci,S.,Pian,D.,2010.Retinalastrocytichamartoma.Optometry81,221–233.Maudsley,S.,Zamah,A.M.,Rahman,N.,Blitzer,J.T.,Luttrell,L.M.,Lefkowitz,R.J.,Hall,R.A.,2000.Platelet-derivedgrowthfactorreceptorassociationwithNa(+)/H(+)ex-changerregulatoryfactorpotentiatesreceptoractivity.Mol.Cell.Biol.20,8352–8363.McClatchey,A.I.,2003.MerlinandERMproteins:unappreciatedrolesincancerdevelop-ment?Nat.Rev.Cancer3,877–883.McClatchey,A.I.,Giovannini,M.,2005.Membraneorganizationandtumorigenesis–theNF2tumorsuppressor,Merlin.GenesDev.19,2265–2277.McMahon,H.T.,Boucrot,E.,2011.Molecularmechanismandphysiologicalfunctionsofclathrin-mediatedendocytosis.Nat.Rev.Mol.CellBiol.12,517–533.Meimoun,P.,Ambard-Bretteville,F.,Colas-desFrancs-Small,C.,Valot,B.,Vidal,J.,2007.Analysisofplantphosphoproteins.Anal.Biochem.371,238–246.Mohler,P.J.,Kreda,S.M.,Boucher,R.C.,Sudol,M.,Stutts,M.J.,Milgram,S.L.,1999.Yes-as-sociatedprotein65localizesp62(c-Yes)totheapicalcompartmentofairwayepithe-liabyassociationwithEBP50.J.CellBiol.147,879–890.Morrison,H.,Sperka,T.,Manent,J.,Giovannini,M.,Ponta,H.,Herrlich,P.,2007.Merlin/neuroﬁbromatosistype2suppressesgrowthbyinhibitingtheactivationofRasandRac.CancerRes.67,520–527.Morrow,K.A.,Das,S.,Meng,E.,Menezes,M.E.,Bailey,S.K.,Metge,B.J.,Buchsbaum,D.J.,Samant,R.S.,Shevde,L.A.,2016.LossoftumorsuppressorMerlinresultsinaberrantactivationofWnt/beta-cateninsignalingincancer.Oncotarget7,17991–18005.Offenhauser,N.,Borgonovo,A.,Disanza,A.,Romano,P.,Ponzanelli,I.,Iannolo,G.,DiFiore,P.P.,Scita,G.,2004.Theeps8familyofproteinslinksgrowthfactorstimulationtoactinreorganizationgeneratingfunctionalredundancyintheRas/Racpathway.Mol.Biol.Cell15,91–98.Pranjol,M.Z.,Gutowski,N.,Hannemann,M.,Whatmore,J.,2015.ThepotentialroleoftheproteasescathepsinDandcathepsinLintheprogressionandmetastasisofepithelialovariancancer.Biomolecules5,3260–3279.Puttmann,S.,Senner,V.,Braune,S.,Hillmann,B.,Exeler,R.,Rickert,C.H.,Paulus,W.,2005.EstablishmentofabenignmeningiomacelllinebyhTERT-mediatedimmortalization.Lab.Investig.85,1163–1171.Qu,Z.,Fu,J.,Yan,P.,Hu,J.,Cheng,S.Y.,Xiao,G.,2010.EpigeneticrepressionofPDZ-LIMdo-main-containingprotein2:implicationsforthebiologyandtreatmentofbreastcan-cer.J.Biol.Chem.285,11786–11792.Rappsilber,J.,Ishihama,Y.,Mann,M.,2003.Stopandgoextractiontipsformatrix-assistedlaserdesorption/ionization,nanoelectrospray,andLC/MSsamplepretreatmentinproteomics.Anal.Chem.75,663–670.Rouleau,G.A.,Merel,P.,Lutchman,M.,Rouleau,G.A.,Merel,P.,Lutchman,M.,Sanson,M.,Zucman,J.,Marineau,C.,Hoang-Xuan,K.,Demczuk,S.,Desmaze,C.,Plougastel,B.,etal.,1993.Alterationinanewgeneencodingaputativemembrane-organizingproteincausesneuro-ﬁbromatosistype2.Nature363,515–521.Sakuda,K.,Kohda,Y.,Matsumoto,T.,Park,C.,Seto,A.,Tohma,Y.,Hasegawa,M.,Kida,S.,Nitta,H.,Yamashima,T.,Yamashita,J.,1996.ExpressionofNF2geneproductmerlininarachnoidvilliandmeningiomas.NoshuyoByori13,145–148.Scherer,S.S.,Gutmann,D.H.,1996.Expressionoftheneuroﬁbromatosis2tumorsuppres-sorgeneproduct,Merlin,inSchwanncells.J.Neurosci.Res.46,595–605.Schulze,K.M.,Hanemann,C.O.,Muller,H.W.,Hanenberg,H.,2002.Transductionofwild-typemerlinintohumanschwannomacellsdecreasesschwannomacellgrowthandinducesapoptosis.Hum.Mol.Genet.11,69–76.Sharma,S.,Ray,S.,Moiyadi,A.,Sridhar,E.,Srivastava,S.,2014.Quantitativeproteomicanalysisofmeningiomasfortheidentiﬁcationofsurrogateproteinmarkers.Sci.Rep.4,7140.Sharma,S.,Ray,S.,Mukherjee,S.,Moiyadi,A.,Sridhar,E.,Srivastava,S.,2015.Multi-prongedquantitativeproteomicanalysesindicatemodulationofvarioussignaltrans-ductionpathwaysinhumanmeningiomas.Proteomics15,394–407.Sheikh,H.A.,Tometsko,M.,Niehouse,L.,Aldeeb,D.,Swalsky,P.,Finkelstein,S.,Barnes,E.L.,Hunt,J.L.,2004.Moleculargenotypingofmedullarythyroidcarcinomacanpredicttumorrecurrence.Am.J.Surg.Pathol.28,101–106.Sun,F.,Xiao,Y.,Qu,Z.,2015.OncovirusKaposisarcomaherpesvirus(KSHV)repressestumorsuppressorPDLIM2topersistentlyactivatenuclearfactorkappaB(NF-kappaB)andSTAT3transcriptionfactorsfortumorigenesisandtumormaintenance.J.Biol.Chem.290,7362–7368.Tanaka,T.,Grusby,M.J.,Kaisho,T.,2007.PDLIM2-mediatedterminationoftranscriptionfactorNF-kappaBactivationbyintranuclearsequestrationanddegradationofthep65subunit.Nat.Immunol.8,584–591.TeVelthuis,A.J.,Isogai,T.,Gerrits,L.,Bagowski,C.P.,2007.Insightsintothemolecularevo-lutionofthePDZ/LIMfamilyandidentiﬁcationofanovelconservedproteinmotif.PLoSOne2,e189.Thang,N.D.,Yajima,I.,Kumasaka,M.Y.,Iida,M.,Suzuki,T.,Kato,M.,2015.Deltex-3-like(DTX3L)stimulatesmetastasisofmelanomathroughFAK/PI3K/AKTbutnotMEK/ERKpathway.Oncotarget6,14290–14299.Topolska-Wos,A.M.,Chazin,W.J.,Filipek,A.,2016.CacyBP/SIP—structureandvarietyoffunctions.Biochim.Biophys.Acta1860,79–85.Torrado,M.,Senatorov,V.V.,Trivedi,R.,Fariss,R.N.,Tomarev,S.I.,2004.Pdlim2,anovelPDZ-LIMdomainprotein,interactswithalpha-actininsandﬁlaminA.Invest.Ophthalmol.Vis.Sci.45,3955–3963.Torres-Martin,M.,Lassaletta,L.,deCampos,J.M.,Isla,A.,Gavilan,J.,Pinto,G.R.,Burbano,R.R.,Latif,F.,Melendez,B.,Castresana,J.S.,Rey,J.A.,2013a.Globalproﬁlinginvestib-ularschwannomasshowscriticalderegulationofmicroRNAsandupregulationinthoseincludedinchromosomalregion14q32.PLoSOne8,e65868.Torres-Martin,M.,Lassaletta,L.,San-Roman-Montero,J.,DeCampos,J.M.,Isla,A.,Gavilan,J.,Melendez,B.,Pinto,G.R.,Burbano,R.R.,Castresana,J.S.,Rey,J.A.,2013b.MicroarrayanalysisofgeneexpressioninvestibularschwannomasrevealsSPP1/METsignalingpathwayandandrogenreceptorderegulation.Int.J.Oncol.42,848–862.Torres-Martin,M.,Lassaletta,L.,Isla,A.,DeCampos,J.M.,Pinto,G.R.,Burbano,R.R.,Castresana,J.S.,Melendez,B.,Rey,J.A.,2014.GlobalexpressionproﬁleinlowgrademeningiomasandschwannomasshowsupregulationofPDGFD,CDH1andSLIT2comparedtotheirhealthytissue.Oncol.Rep.32,2327–2334.Tyanova,S.,Temu,T.,Sinitcyn,P.,Carlson,A.,Hein,M.Y.,Geiger,T.,Mann,M.,Cox,J.,2016.ThePerseuscomputationalplatformforcomprehensiveanalysisof(prote)omicsdata.Nat.Methods.vanTilborg,A.A.,AlAllak,B.,Velthuizen,S.C.,deVries,A.,Kros,J.M.,Avezaat,C.J.,deKlein,A.,Beverloo,H.B.,Zwarthoff,E.C.,2005.Chromosomalinstabilityinmeningiomas.J.Neuropathol.Exp.Neurol.64,312–322.Wang,X.,Gong,Y.,Wang,D.,Xie,Q.,Zheng,M.,Zhou,Y.,Li,Q.,Yang,Z.,Tang,H.,Li,Y.,Hu,R.,Chen,X.,Mao,Y.,2012.Analysisofgeneexpressionproﬁlinginmeningioma:deregulatedsignalingpathwaysassociatedwithmeningiomaandEGFL6overexpres-sioninbenignmeningiomatissueandserum.PLoSOne7,e52707.Weinman,E.J.,Steplock,D.,Donowitz,M.,Shenolikar,S.,2000.NHERFassociationswithsodium-hydrogenexchangerisoform3(NHE3)andezrinareessentialforcAMP-me-diatedphosphorylationandinhibitionofNHE3.Biochemistry39,6123–6129.Yang,H.W.,Kim,T.M.,Song,S.S.,Shrinath,N.,Park,R.,Kalamarides,M.,Park,P.J.,Black,P.M.,Carroll,R.S.,Johnson,M.D.,2012.AlternativesplicingofCHEK2andcodeletionwithNF2promotechromosomalinstabilityinmeningioma.Neoplasia14,20–28.Zhang,Y.,Wen,Z.,Washburn,M.P.,Florens,L.,2009.Effectofdynamicexclusiondurationonspectralcountbasedquantitativeproteomics.Anal.Chem.81,6317–6326.Zhao,B.,Li,L.,Lei,Q.,Guan,K.L.,2010.TheHippo-YAPpathwayinorgansizecontrolandtumorigenesis:anupdatedversion.GenesDev.24,862–874.Zhao,L.,Yu,C.,Zhou,S.,Lau,W.B.,Lau,B.,Luo,Z.,Lin,Q.,Yang,H.,Xuan,Y.,Yi,T.,Zhao,X.,Wei,Y.,2016.EpigeneticrepressionofPDZ-LIMdomain-containingprotein2pro-motesovariancancerviaNOS2-derivednitricoxidesignaling.Oncotarget7,1408–1420.Zhou,L.,Ercolano,E.,Ammoun,S.,Schmid,M.C.,Barczyk,M.A.,Hanemann,C.O.,2011.Merlin-deﬁcienthumantumorsshowlossofcontactinhibitionandactivationofWnt/beta-cateninsignalinglinkedtothePDGFR/SrcandRac/PAKpathways.Neopla-sia13,1101–1112.86K.Bassirietal./EBioMedicine16(2017)76–86